Clouds loom for Novartis’s MorphoSys buy
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
Not so B-Fast for Roche
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
An alpha turnaround for Relay
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
